The Latest Breaking News from Protagonist Therapeutics

A Weekly Shot Spared Three in Four Blood Cancer Patients from Repeat Blood Draws, and the FDA Just Approved It

FDA approved Mimrylo for polycythemia vera, the first hepcidin-mimicking drug for a blood cancer affecting about 90,000 Americans.

Medical Daily · Aug 31

Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks. PTGX holds a 100% “Buy” technical opinion from Barchart. Despite bullish analyst sentiment and price targets up to $137, I remain cautious due to low price stability, high short interest, and erratic earnings predictions....

Barchart · Jul 2

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Johnson Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).

Benzinga · Oct 10, 2025